SEShadi Esmaeili

Shadi Esmaeili

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shadi Esmaeili has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Aryan Salahi‐Niri

    Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Ali Ahmadi

    Affiliation Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Amir Abas Navidinia

    Affiliations Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Aryan Salahi-Niri

    Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Behzad Poopak

    Affiliation Department of Medical Laboratory Sciences, Faculty of Paramedical Sciences, Islamic Azad University, Tehran, Iran

    1 shared publication
  • Davood Bashash

    Affiliation Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication

Latest Publications

  • Open Access

    ZnO Q-Dots Nanoparticles: Intensifying ROS Stress to Improve Anticancer Drug Efficacy

    by Davood Bashash, Aryan Salahi-Niri, Zahra Fakhroueian, Shadi Esmaeili

    Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia that is effectively treated with arsenic trioxide (ATO) in combination with all-trans retinoic acid. However, the toxic effects of ATO necessitate exploring safer therapeutic combinations. Nanotechnology offers potential strategies to enhance drug efficacy and safety. Zinc oxide quantum dots (ZnO Q-dots) exhibit properties such as biocompatibility, selectivity, and the ability to induce reactive oxygen species (ROS), which may potentiate anticancer drug effects. Objectives: This study investigated the combined use of ZnO Q-dots and ATO to improve anticancer outcomes in NB4 APL-derived cells. Methods: NB4 cells were treated with varying concentrations of ZnO Q-dots and ATO, either alone or in combination. Cell viability was assessed using the trypan blue exclusion assay and the MTT assay. Proliferation was evaluated using the BrdU assay, and cell cycle distribution was analyzed by flow cytometry. Apoptosis- and autophagy-related markers were assessed using quantitative real-time PCR (qRT-PCR), and ROS levels were measured using a fluorogenic dye. Results: ZnO Q-dots enhanced the antiproliferative and apoptotic effects of ATO in a dose- and time-dependent manner. Combined treatment reduced metabolic activity to 39.7 ± 2.6%, corresponding to approximately 60.3% inhibition relative to controls. Significant upregulation of apoptotic genes (e.g., p53, Bax) and downregulation of anti-apoptotic genes (e.g., Bcl-2) were observed. ROS production was markedly increased, accompanied by induction of autophagy-related genes (ATG-7, Beclin-1). Conclusions: The combination of ZnO Q-dots and ATO enhances anticancer efficacy in APL-derived NB4 cells, primarily by increasing ROS production, apoptosis, and autophagy. These findings suggest a promising therapeutic strategy with improved efficacy compared with that of single-agent treatments.

  • Open Access

    Derivation of a novel multi‐gene prognostic model based on regulated cell death pathways in acute myeloid leukemia: A comprehensive bioinformatic analysis integrating gene expression, mutation profiling, and immune infiltration

    by Ali Ahmadi, Amir Abas Navidinia, Davood Bashash, Behzad Poopak, Shadi Esmaeili

    Background: Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy with dismal survival outcomes, where dysregulation of regulated cell death (RCD) pathways plays a pivotal role in leukemogenesis and therapeutic resistance. Methods: Differential expression analyses were performed comparing AML samples with healthy bone marrow. Diagnostic differentially expressed genes (DEGs) were then intersected with curated gene sets representing apoptosis, pyroptosis, autophagy, necroptosis, and ferroptosis to derive an RCD-based gene signature. Prognostic markers were identified by univariate Cox regression, and these markers were refined using LASSO regression to construct a multi-gene prognostic model that generated an individual risk score (RS) for each patient. The performance of the model was validated internally through Kaplan–Meier survival analyses and receiver operating characteristic (ROC) curves for 1-, 3-, and 5-year survival, and externally confirmed in an independent TARGET-AML cohort. In addition, mutation analysis was conducted using the maftools package, and immune infiltration profiling was performed with CIBERSORT and xCell to characterize the molecular landscape of the risk groups. Results: Our integrative approach yielded a four-gene prognostic model incorporating ARHGEF35, GSN, ELANE, and AKT3. High RS was strongly associated with adverse overall survival, with Kaplan–Meier analyses showing p-value < 0.0001 in the training cohort and p-value = 0.0026 in the testing cohort. The model demonstrated robust predictive accuracy with AUC values of 82%, 87%, and 91% for 1-, 3-, and 5-year survival in the training set, and 65%, 81%, and 94% in the testing set. Mutation analysis revealed that DNMT3A and RUNX1 mutations were significantly enriched in high-RS patients (p-value = 0.0015 and p-value = 0.0086, respectively), whereas KIT mutations were more prevalent in low-RS patients (p-value = 0.0058). Immune profiling indicated that high-RS patients had increased M2 macrophage infiltration (p-value = 0.0027) and reduced resting mast cells (p-value = 0.0033). Conclusion: These findings establish that an RCD-based multi-gene risk model can robustly stratify AML patients by prognosis and illuminate underlying genomic and immunologic mechanisms, thereby offering promising avenues for personalized therapeutic strategies.

  • Open Access

    Nanotechnology in Hematology: Enhancing Therapeutic Efficacy With Nanoparticles

    by Nima Torabi Fard, Melika Khademi, Aryan Salahi‐Niri, Shadi Esmaeili

    Background and Aims: Hematological malignancies, such as leukemia, lymphoma, and multiple myeloma, contribute significantly to global cancer diagnoses. Despite progress in conventional therapies, such as chemotherapy and immunotherapy, these treatments face limitations, including nonspecific targeting, side effects, and drug resistance. The aim of this review is to explore the potential of nanotechnology, particularly nanoparticles (NPs), to improve therapeutic outcomes for these cancers by enhancing drug delivery and reducing toxicity. Methods: This review examines recent advancements in NP‐based therapies, focusing on their application in hematological malignancies. We discuss different types of NPs, including liposomes, polymeric, and inorganic NPs, for their potential in targeted drug delivery. The review also evaluates the current state of clinical trials and highlights challenges in the translation of nanomedicines from preclinical research to clinical practice. Results: Nanoparticles, with their unique properties, offer significant advantages in drug delivery systems, such as enhanced stability, extended circulation time, and targeted tumor delivery. Various NP formulations have shown promise in clinical trials, including liposomal formulations like Vyxeos for acute myeloid leukemia and Marqibo for Ph‐negative acute lymphoblastic leukemia. However, challenges in toxicity, regulatory hurdles, and large‐scale production still remain. Conclusion: Nanomedicine holds transformative potential in the treatment of hematological malignancies, offering more effective and specific therapies compared to conventional treatments. Continued research is necessary to overcome the clinical challenges and maximize the benefits of NP‐based therapies for patients with blood cancers.


  • Open Access

    DNA Methylation-Dependent Regulation of Lipoprotein Lipase Expression During Human Mesenchymal Stem Cell Differentiation into Adipocytes

    by Seied Rasoul Razavi Babaheidari, Aryan Salahi-Niri, Mohammad Hossein Mohammadi, Mohsen Hamidpour, Shadi Esmaeili

    Background: Lipoprotein lipase (LPL) is a critical enzyme in lipid metabolism that hydrolyzes triglyceride-rich lipoproteins. While its role in mature adipose tissue is well understood, the epigenetic regulation of LPL during mesenchymal stem cell (MSC) differentiation into adipocytes remains poorly characterized. This study aimed to investigate the temporal expression pattern of ...